MX2020000968A - Compuestos organicos. - Google Patents
Compuestos organicos.Info
- Publication number
- MX2020000968A MX2020000968A MX2020000968A MX2020000968A MX2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A MX 2020000968 A MX2020000968 A MX 2020000968A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- receptor
- organic compounds
- involving
- carbolines
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se refiere a gamma carbolinas fusionadas con heterociclo sustituido particulares, sus profármacos, en forma libre, sólida, sal farmacéuticamente aceptable y/o sustancialmente pura como se describe en la presente, composiciones farmacéuticas de los mismos, y métodos de uso en el tratamiento de enfermedades que implican el receptor 5??HT2A, el transportador de serotonina (SERT), las vías que involucran el sistema de señalización del receptor de dopamina D1 y Dz, y/o el receptor opioide p.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762537287P | 2017-07-26 | 2017-07-26 | |
US201862639244P | 2018-03-06 | 2018-03-06 | |
US201862682546P | 2018-06-08 | 2018-06-08 | |
PCT/US2018/043100 WO2019023062A1 (en) | 2017-07-26 | 2018-07-20 | ORGANIC COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020000968A true MX2020000968A (es) | 2020-09-28 |
Family
ID=65040269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000968A MX2020000968A (es) | 2017-07-26 | 2018-07-20 | Compuestos organicos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11376249B2 (es) |
EP (1) | EP3658145A4 (es) |
JP (1) | JP7223742B2 (es) |
KR (1) | KR20200033307A (es) |
CN (1) | CN111093665A (es) |
AU (1) | AU2018307479A1 (es) |
BR (1) | BR112020001666A2 (es) |
CA (1) | CA3071119A1 (es) |
IL (1) | IL272249B2 (es) |
MX (1) | MX2020000968A (es) |
WO (1) | WO2019023062A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3791879A1 (en) | 2012-04-14 | 2021-03-17 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
IL309536A (en) | 2016-01-26 | 2024-02-01 | Intra Cellular Therapies Inc | organic compounds |
EP3525763A4 (en) | 2016-10-12 | 2020-06-17 | Intra-Cellular Therapies, Inc. | AMORPHE FIXED DISPERSIONS |
BR112019019875A2 (pt) | 2017-03-24 | 2020-04-22 | Intra Cellular Therapies Inc | novas composições e métodos |
CN111093664B (zh) | 2017-07-26 | 2023-06-02 | 细胞内治疗公司 | 有机化合物 |
CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
EP3843739A4 (en) * | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
KR20210052471A (ko) * | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
WO2020131911A1 (en) * | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
MX2021007141A (es) * | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
AU2020212019A1 (en) * | 2019-01-23 | 2021-09-16 | Intra-Cellular Therapies, Inc. | Methods of treating addiction |
US20220362241A1 (en) * | 2019-09-25 | 2022-11-17 | Intra-Cellular Therapies, Inc. | Novel methods |
JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
WO2022132182A1 (en) * | 2020-12-18 | 2022-06-23 | Hung, Shu-Mei | Feed pipe height adjustment mechanism for livestock feeding systems |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
ATE90683T1 (de) | 1986-03-19 | 1993-07-15 | Kumiai Chemical Industry Co | 5h-1,3,4-thiazol(3,2-a>pyrimidin-5-on-derivate und diese enthaltende fungizide zubereitungen. |
ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
JP2848060B2 (ja) | 1991-10-24 | 1999-01-20 | 株式会社日立製作所 | プログラマブルコントローラおよびシーケンス制御方法 |
IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
WO1995013814A1 (en) | 1993-11-19 | 1995-05-26 | Janssen Pharmaceutica N.V. | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
WO1999018057A1 (en) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation of diaryl ether by condensation reactions |
US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
WO1999043643A2 (en) | 1998-02-26 | 1999-09-02 | Massachusetts Institute Of Technology | Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes |
US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
EP1097158B1 (en) | 1998-07-10 | 2006-01-25 | Massachusetts Institute Of Technology | Ligands for metals and metal-catalyzed processes |
US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
PT1140012E (pt) | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
ES2228549T3 (es) * | 1999-06-15 | 2005-04-16 | Bristol-Myers Squibb Pharma Company | Gamma-carbolinas condensadas con heterociclo sustituido. |
US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
SK7042003A3 (en) | 2000-12-20 | 2004-07-07 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists |
DK1390340T3 (en) | 2001-04-24 | 2017-05-15 | Massachusetts Inst Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
EP1414819B1 (en) | 2001-08-08 | 2005-10-12 | Pharmacia & Upjohn Company LLC | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
DK1539115T3 (da) | 2002-07-29 | 2008-01-28 | Alza Corp | Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
CN1684944A (zh) | 2002-08-02 | 2005-10-19 | 麻省理工学院 | 铜催化形成碳-杂原子和碳-碳键的方法 |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
PL377426A1 (pl) | 2002-12-19 | 2006-02-06 | Bristol-Myers Squibb Company | Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego |
JP2006528187A (ja) | 2003-07-21 | 2006-12-14 | スミスクライン ビーチャム コーポレーション | (2S,4S)−4−フルオロ−1−[4−フルオロ−β−(4−フルオロフェニル)−L−フェニルアラニル]−2−ピロリジンカルボニトリルp−トルエンスルホン酸塩及びその無水結晶形態 |
JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
WO2005095396A1 (en) | 2004-03-05 | 2005-10-13 | Pharma C S.A. | 8-phenoxy-ϝ carboline derivatives |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
EP1793671B1 (en) | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
CA2581023A1 (en) | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
ATE457989T1 (de) | 2004-12-15 | 2010-03-15 | Hoffmann La Roche | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit |
CA2595711A1 (en) | 2005-01-25 | 2006-08-03 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
AU2007206016A1 (en) | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
AU2008226814C1 (en) | 2007-03-12 | 2014-11-20 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
CN101842010A (zh) | 2007-08-01 | 2010-09-22 | 梅迪维新神经学公司 | 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物 |
US8791138B2 (en) | 2008-02-05 | 2014-07-29 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
DK2262505T3 (en) | 2008-03-12 | 2015-01-05 | Intra Cellular Therapies Inc | Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID |
KR102317698B1 (ko) | 2008-05-27 | 2021-10-25 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
CA2796756A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
EP3791879A1 (en) | 2012-04-14 | 2021-03-17 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
EP2968320B1 (en) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR102421656B1 (ko) | 2013-12-03 | 2022-07-15 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
EP3125892A4 (en) | 2014-04-04 | 2017-12-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
BR112016023162B1 (pt) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
IL309536A (en) * | 2016-01-26 | 2024-02-01 | Intra Cellular Therapies Inc | organic compounds |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN111093664B (zh) * | 2017-07-26 | 2023-06-02 | 细胞内治疗公司 | 有机化合物 |
US20210009592A1 (en) | 2018-03-23 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3801527A4 (en) * | 2018-06-08 | 2022-03-30 | Intra-Cellular Therapies, Inc. | NEW METHODS |
-
2018
- 2018-07-20 AU AU2018307479A patent/AU2018307479A1/en active Pending
- 2018-07-20 BR BR112020001666-7A patent/BR112020001666A2/pt unknown
- 2018-07-20 JP JP2020503842A patent/JP7223742B2/ja active Active
- 2018-07-20 MX MX2020000968A patent/MX2020000968A/es unknown
- 2018-07-20 CA CA3071119A patent/CA3071119A1/en active Pending
- 2018-07-20 EP EP18838429.1A patent/EP3658145A4/en active Pending
- 2018-07-20 US US16/634,055 patent/US11376249B2/en active Active
- 2018-07-20 IL IL272249A patent/IL272249B2/en unknown
- 2018-07-20 CN CN201880057546.7A patent/CN111093665A/zh active Pending
- 2018-07-20 WO PCT/US2018/043100 patent/WO2019023062A1/en active Application Filing
- 2018-07-20 KR KR1020207005454A patent/KR20200033307A/ko not_active Application Discontinuation
-
2022
- 2022-06-03 US US17/832,282 patent/US20220296591A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11376249B2 (en) | 2022-07-05 |
WO2019023062A1 (en) | 2019-01-31 |
KR20200033307A (ko) | 2020-03-27 |
US20220296591A1 (en) | 2022-09-22 |
CN111093665A (zh) | 2020-05-01 |
BR112020001666A2 (pt) | 2020-07-21 |
CA3071119A1 (en) | 2019-01-31 |
RU2020107841A3 (es) | 2021-09-27 |
AU2018307479A1 (en) | 2020-02-27 |
IL272249A (en) | 2020-03-31 |
RU2020107841A (ru) | 2021-08-26 |
IL272249B1 (en) | 2023-07-01 |
US20210145829A1 (en) | 2021-05-20 |
EP3658145A4 (en) | 2021-04-21 |
JP7223742B2 (ja) | 2023-02-16 |
IL272249B2 (en) | 2023-11-01 |
JP2020528431A (ja) | 2020-09-24 |
EP3658145A1 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020000968A (es) | Compuestos organicos. | |
MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
MX2021014508A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
MX2020000967A (es) | Compuestos organicos. | |
MX2016013046A (es) | Compuestos organicos. | |
MX339805B (es) | Compuestos organicos. | |
MX2014012374A (es) | Compuestos organicos. | |
MX2020009929A (es) | Compuestos organicos. | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
PH12017501061A1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
NZ747259A (en) | Soluble c5ar antagonists | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
ATE536172T1 (de) | Ezetimibzusammensetzungen | |
MX2020009928A (es) | Compuestos organicos. | |
EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
MY179783A (en) | Substituted bicyclic compounds | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
EA201890412A1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ | |
MX2021007217A (es) | Compuesto organico. | |
MX2017016939A (es) | Novedosas antagonistas 5-ht2. | |
PH12017501736A1 (en) | Indole derivatives | |
EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
WO2023178113A3 (en) | Organic compounds |